Two-Drug attack on blood cancer enters testing
NCT ID NCT07269470
Summary
This study is testing whether combining two drugs, dasatinib and ropeginterferon, is safe and effective for controlling chronic myeloid leukemia (CML) in newly diagnosed patients. The goal is to see if this combination can drive the cancer down to very low levels in the blood. About 40 adult patients will receive the drug combination and be monitored for up to 10 years to track their response and any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.